ScripsAmerica Inc. (SCRCQ)

[kenbe]

It was an opinion stated by the SeethruEquity Research Group of the company. It wasn't a quote from the CEO.
Thanks TuT I knew exactly where it was but wanted someone to just post what they were boasting about




SeeThruEquity Initiates Research Coverage on ScripsAmerica with a Price Target of $1.20

This article was originally distributed via SproutNews. SproutNews, WorldNow and this Site make no warranties or representations in connection therewith.
New York, NY / ACCESSWIRE / December 2, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on ScripsAmerica, Inc. (OTCQB: SCRC) with a 12-month price target of $1.20.

The report is available here: SCRC Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

In our estimation ScripsAmerica is an undervalued speculative growth company in the medical industry. The company has experienced robust growth in its specialty pharmacy segment since the launch of this business, with orders that surpassed a $60mn annual run rate in October. The specialty pharmacy business specializes in compounding, or the mixing of drugs by a pharmacist to fit the unique needs of a patient. It is a high margin business that we expect can drive positive free cash flow for ScripsAmerica as soon as the second half of this year. Additionally, we see several potential catalysts over the next twelve months as the company expands its presence in specialty pharmacy and prepares for the commercial launch of a branded over-the-counter (“OTC”) product called RapiMed, which is a children’s pain reliever and fever reducer using the company’s oral delivery technology.

“We see several potential catalysts ahead for ScripsAmerica. We expect the company to release its new RapiMed product line of acetaminophen for children’s pain and fever relief utilizing its oral delivery technology in Hong Kong during the fourth quarter of 2014. Further, we suspect that investors may have overlooked the substantial operating progress made in the company’s high margin specialty pharmacy business. In fact we expect this progress will enable ScripsAmerica to generate positive adjusted operating income and cash flow in the back half of the year, as was demonstrated by strong 3Q14 results released,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $1.20 per share.”